ImmuCell (NASDAQ:ICCC) Share Price Passes Above 200-Day Moving Average – Here’s Why

ImmuCell Corporation (NASDAQ:ICCC) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $5.93 and traded as high as $6.25. ImmuCell shares last traded at $6.25, with a volume of 6,898 shares trading hands.

ImmuCell Stock Up 4.9%

The business has a 50 day simple moving average of $6.30 and a 200 day simple moving average of $5.93. The stock has a market cap of $56.56 million, a PE ratio of 32.90 and a beta of 0.29. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.85 and a quick ratio of 1.99.

ImmuCell (NASDAQ:ICCC) last announced its quarterly earnings results on Thursday, August 14th. The biotechnology company reported $0.06 earnings per share for the quarter. ImmuCell had a return on equity of 6.25% and a net margin of 6.23%.The company had revenue of $6.45 million during the quarter.

Institutional Trading of ImmuCell

A number of institutional investors and hedge funds have recently made changes to their positions in ICCC. Citadel Advisors LLC acquired a new stake in shares of ImmuCell in the fourth quarter worth about $149,000. Northern Trust Corp lifted its position in shares of ImmuCell by 51.0% in the fourth quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company’s stock worth $229,000 after buying an additional 14,982 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of ImmuCell by 4.2% in the second quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock worth $500,000 after buying an additional 2,907 shares during the last quarter. Institutional investors and hedge funds own 13.47% of the company’s stock.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.